Stephen Liu, MD, MedStar Georgetown University Hospital

Articles by Stephen Liu, MD, MedStar Georgetown University Hospital

NSCLC Management: Second-Line Options

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

Squamous Cell Frontline Therapy: IMpower 131, KEYNOTE-407

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

CheckMate 817 Overview

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

PD-L1 Combination Therapy Clinical Trials

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

Frontline PD-L1 Monotherapy: KEYNOTE-042 and IMpower110

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

CheckMate-9LA: Histology and Frontline Impact

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

Recent Combination Approval: CheckMate-9LA Regimen

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

CheckMate-227 Regimen Safety Profile

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

ASCO 2020 Data Update: CheckMate 227

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

Nondriver Adenocarcinoma: Determining Therapy

ByNeal E. Ready, MD, PhD, Duke University Medical Center,Stephen Liu, MD, MedStar Georgetown University Hospital

July 16th 2020

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Second- and Third-Line Treatment for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Expert Approaches to Treating Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Latest Updated Articles

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC
July 6th 2020
PD-L1 Combination Therapy Clinical Trials
July 16th 2020
NSCLC Management: Second-Line Options
July 16th 2020
Review of Treatment for Limited-Stage Small-Cell Lung Cancer
July 6th 2020
Role of PCI Versus Brain MRI Surveillance in ES-SCLC
July 6th 2020
CheckMate-227 Regimen Safety Profile
July 16th 2020

Stephen Liu, MD, MedStar Georgetown University Hospital

Articles by Stephen Liu, MD, MedStar Georgetown University Hospital

NSCLC Management: Second-Line Options

Squamous Cell Frontline Therapy: IMpower 131, KEYNOTE-407

CheckMate 817 Overview

PD-L1 Combination Therapy Clinical Trials

Frontline PD-L1 Monotherapy: KEYNOTE-042 and IMpower110

CheckMate-9LA: Histology and Frontline Impact

Recent Combination Approval: CheckMate-9LA Regimen

CheckMate-227 Regimen Safety Profile

ASCO 2020 Data Update: CheckMate 227

Nondriver Adenocarcinoma: Determining Therapy

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

Second- and Third-Line Treatment for ES-SCLC

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

Expert Approaches to Treating Extensive Stage SCLC

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

Latest Updated Articles

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL